As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Study identifier: NCT01749397
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Metastatic epithelial ovarian, primary peritoneal, or fallopian tube cancer for which standard curative measures do not exist, no prior PARP inhibitor.
Type of study:
Phase I study
21-day cycles with veliparib intravenously on days 1-10 and floxuridine intraperitoneal on days 3-5
Johns Hopkins University
Contact: Deborah K. Armstrong 410-955-8804 email@example.com
Principal Investigator: Deborah K. Armstrong
Contact: Andrea E. Wahner Hendrickson 507-284-2511 firstname.lastname@example.org